Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Pancreatic Cancer Early Detection Consortium

Arbor Research Collaborative for Health · NCT04970056

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–90 · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
20000
US sites recruiting
40
Study start
September 18, 2020
Record last updated
July 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Conditions: Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:

Cohort 1

Individuals without history of PDAC meeting any of the following criteria:

  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
  • 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
  • Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
  • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+

Cohort 2

Individuals without history of PDAC meeting any of the following criteria:

  • ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
  • 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
  • 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member

Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)

Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.

Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.

Cohort 6a

Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:

  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11

Cohort 6b

Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:

  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • Diagnosed ≤ age 45

Cohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.

Cohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.

Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Exclusion Criteria

  • Individuals not meeting the criteria above.

Recruiting US locations

  • Honor Health Research Institute

    Scottsdale, AZ 85258

    Site contact: Jeanette Dupree · jdupree@honorhealth.com

  • Providence Health and Services

    Burbank, CA 91505

    Site contact: Taridu Ekanayake · emtaridu.ekanayake@providence.org

  • City of Hope

    Duarte, CA 91010

    Site contact: Diamond Ward · diward@coh.org

  • UC San Diego Moores Cancer Center

    La Jolla, CA 92093

    Site contact: Emma Vail · e2brooks@health.ucsd.edu

  • Cedars-Sinai Medical Center

    Los Angeles, CA 90048

    Site contact: Jenny Frisendahl · jenny.frisendahl@cshs.org

  • UCLA Health

    Los Angeles, CA 90095

    Site contact: Sophia Quiroz · SStokes@mednet.ucla.edu

  • Hoag

    Newport Beach, CA 92663

    Site contact: Alexandria Adams · alexandria.adams@hoag.org

  • UC Irvine Health

    Orange, CA 92868

    Site contact: Blake Johnson · blakej@hs.uci.edu

  • UC Davis

    Sacramento, CA 95817

    Site contact: Tanpreet Dodd · tkdodd@health.ucdavis.edu

  • University of California, San Francisco (UCSF)

    San Francisco, CA 94143

    Site contact: Kurt Giles · PancreasCRC@ucsf.edu

  • Yale University

    New Haven, CT 06510

    Site contact: Scott Merenda · scott.merenda@yale.edu

  • Mayo Clinic Jacksonville

    Jacksonville, FL 32224

    Site contact: Christian Glover · glover.christian@mayo.edu

  • University of Miami

    Miami, FL 33136

    Site contact: Casper Ruiz Ruiz · cxr1353@med.miami.edu

  • Moffitt Cancer Center

    Tampa, FL 33612

    Site contact: Toni Basinski · 813.745.6360 · Toni.Basinski@Moffitt.Org

  • Emory University Hospital

    Atlanta, GA 30322

    Site contact: Halley Fowler · halley.fowler@emory.edu

  • Illinois CancerCare

    Bloomington, IL 61704

    Site contact: Carrie Geoffroy · cgeoffroy@illinoiscancercare.com

  • University of Chicago Medicine

    Chicago, IL 60637

    Site contact: Nia Howard · nia.howard@bsd.uchicago.edu

  • NorthShore University HealthSystem

    Evanston, IL 60201

    Site contact: Aram Rojas · arojas@northshore.org

  • University of Kansas Medical Center

    Kansas City, KS 66160

    Site contact: Jodi Claybaugh · jclaybaugh@kumc.edu

  • Massachusetts General Hospital

    Boston, MA 02114

    Site contact: Danielle Lynch · dlynch22@mgh.harvard.edu

  • Umass Memorial Medical Center

    Worcester, MA 01655

    Site contact: Paige Malone · paige.malone@umassmed.edu

  • University of Michigan

    Ann Arbor, MI 48109

    Site contact: Sarah Volk · stomanic@med.umich.edu

  • Beaumont/Corewell Health

    Royal Oak, MI 48073

    Site contact: Tara Rangarajan · tara.rangarajan@corewellhealth.org

  • University of Nebraska Medical Center

    Omaha, NE 68198

    Site contact: Suzanne Wessling · suzanne.wessling@unmc.edu

  • Hackensack Meridian Health

    Hackensack, NJ 07601

    Site contact: Christianna Torres · christianna.torres@hmhn.org

  • Icahn School of Medicine At Mount Sinai

    New York, NY 10029

    Site contact: Joyce Serebrenik · joyce.serebrenik@mountsinai.org

  • Columbia University Irving Medical Center

    New York, NY 10032

    Site contact: Katharine Godfrey · kb3217@cumc.columbia.edu

  • University of Rochester Medical Center

    Rochester, NY 14642

    Site contact: Chelsea DiBella · chelsea_dibella@urmc.rochester.edu

  • White Plains Hospital

    White Plains, NY 10601

    Site contact: Griselda Cruz · grcruz@wphospital.org

  • The Ohio State University

    Columbus, OH 43210

    Site contact: Ashley Tyson · 614-814-6487 · Ashley.Tyson@osumc.edu

  • Oregon Health & Science University

    Portland, OR 97239

    Site contact: Dove Keith · keithd@ohsu.edu

  • University of Pennsylvania

    Philadelphia, PA 19104

    Site contact: Danny Clay · Daniel.Clay@Pennmedicine.upenn.edu

  • Fox Chase Cancer Center

    Philadelphia, PA 19111

    Site contact: Eberechukwu Muoneke · eberechukwu.muoneke@fccc.edu

  • University of Pittsburgh Medical Center (Upmc)

    Pittsburgh, PA 15232

    Site contact: Beth Dudley · dudleyre@upmc.edu

  • University of Tennessee Graduate School of Medicine

    Knoxville, TN 37930

    Site contact: Tiffany Johnson · thjohnson@utmck.edu

  • Huntsman Cancer Institute

    Salt Lake City, UT 84112

    Site contact: Jo Lyman · jo.anson@hci.utah.edu

  • University of Virginia

    Charlottesville, VA 22903

    Site contact: Evelyn Garcia · ev4pd@uvahealth.org

  • Inova Schar Cancer Institute

    Fairfax, VA 22031

    Site contact: Salman Baig · Salman.Baig@inova.org

  • VCU Massey Comprehensive Cancer Center

    Richmond, VA 23298

    Site contact: Faith McFadden · mcfaddenfr@vcu.edu

  • University of Washington

    Seattle, WA 98195

    Site contact: Lisa Ann Lai · lail@uw.edu

Study contacts (from the official record)

  • Naveen Fawas, BS · 7346654108 · naveen.fawaz@arborresearch.org
  • John Graff, PhD · 7346654108 · john.graff@arborresearch.org
All healthy volunteers studies in Arizona →
Pancreatic Cancer Early Detection Consortium (NCT04970056) | Bored Studies